Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients.
OBJECTIVE
To describe clinical experience with atovaquone suspension for the treatment of Pneumocystis carinii pneumonia (PCP) in HIV-infected patients.


METHODS
A retrospective chart review.


METHODS
The medical records of 54 HIV-infected patients with PCP treated with atovaquone were examined. The outcomes of 34 patients treated with atovaquone suspension (750 mg twice a day) were compared with those of 20 patients treated with atovaquone tablets (750 mg three times a day).


RESULTS
The proportion of patients successfully treated was similar with the suspension (74%) and tablet (70%) formulations of atovaquone. The proportion of patients with an inadequate response to therapy was lower for patients treated with atovaquone suspension (15%) than tablets (30%). Both formulations were well tolerated.


CONCLUSIONS
Atovaquone suspension is effective and well tolerated for the treatment of PCP.
Rosenberg
D M
DM
Epidemiology Division, Glaxo Wellcome R&D, Greenford, UK. dr74409@glaxowellcome.co.uk
McCarthy
W
W
Slavinsky
J
J
Chan
C K
CK
Montaner
J
J
Braun
J
J
Dohn
M N
MN
Caldwell
P T
PT
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D053626:Atovaquone; D005260:Female; D006801:Humans; D008297:Male; D009285:Naphthoquinones / Q000627:therapeutic use*; D019999:Pharmaceutical Solutions; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D012189:Retrospective Studies; D013607:Tablets; D016896:Treatment Outcome
D000935:Antifungal Agents; D009285:Naphthoquinones; D019999:Pharmaceutical Solutions; D013607:Tablets; D053626:Atovaquone